Product Description
nCD64 is a type of integral membrane glycoprotein known as Fc receptor that binds monomeric IgG with high affinity (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654214/)
Mechanisms of Action: CD64 Analogue
Novel Mechanism: Yes
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Assiut University
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ChiCTR1900027227 | N/A |
Not yet recruiting |
Other |
2020-12-31 |